RxDoctor Payments Data

Zachary Freestone, DO

Nephrology · American Fork, UTNPI 1790070449

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $473, 4.2 times the $111 reported in 2019. That places this record below the midpoint for nephrology clinicians in UT, where the typical reported total is $1,171.

$1,016in general payments, 2019–2025

Across 50 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$214
  • Bayer$119
  • ANI Pharmaceuticals, Inc.$110
  • Novartis$81
  • Amgen$79
  • Ardelyx, Inc.$77
  • plus $335 from 12 others

What the payments were for

  • Food & beverage$1,012100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,016 in reported general payments places this provider in the 45th percentile of 74 nephrology providers in Utah.

See all nephrology providers in Utah

Medicare billing

Part B allowed, 2024
$156,787
Medicare patients
377
Services billed
4,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LokelmaSodium Zirconium Cyclosilicate17$13,623
Calcitriol103$1,962
Mycophenolate Mofetil19$1,708
Losartan Potassium64$921
Carvedilol42$816
Amlodipine Besylate65$731
Potassium Chloride23$502
Valsartan21$465
Tamsulosin Hcl19$353
Allopurinol37$337
Torsemide13$324
Bumetanide14$307
Furosemide49$274
Lisinopril19$231
Levothyroxine Sodium23$213

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$34$13,62317 claims
ANI Pharmaceuticals, Inc.Valsartan$110$46521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 74 nephrology providers in Utah.

Other nephrology in American Fork

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →